Kyrgyzpharmacy: orders have increased almost sixfold in two years

The state-owned enterprise Kyrgyzpharmacy responded to criticism voiced during public hearings on the draft republican budget for 2026. The company stated that it shares concerns about drug supply, but that some of the problems are not related to its activities, but to systemic failures in the work of medical organisations and drug registration processes.

Kyrgyzpharmacy pointed out that the company was established only two years ago and has accomplished a tremendous amount of work during that time:

• the volume of orders has grown almost sixfold, from 1 billion KGS in 2023 to 5.78 billion KGS in 2025;
• the number of contracts has increased from 26 to 257, of which more than 80 are directly with foreign manufacturers;
• in the first half of 2025 alone, centralised deliveries amounted to 2.43 billion KGS;
• a digital platform for transparent monitoring of applications has been introduced for the first time;
• A pilot project has been launched to deliver medicines to the regions via Kyrgyz Post.

At the same time, the company operates on a limited budget: since its creation, working capital has not been increased and remains at 800 million KGS — only 13.8% of the 2025 procurement volume.

The company emphasises that work is continuing: warehouses are being built, negotiations on long-term contracts are underway, an independent audit is being prepared, and cooperation with major international manufacturers and organisations is expanding.

‘We are open to dialogue and invite all parties to work together. The goal is not only transparent and timely deliveries, but also to restore confidence in the system as a whole,’ Kyrgyzpharmacy said.